Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning

Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2 Akihiro Nishida,1,2 Yasuo Kurimoto1,2 1Department of Ophthalmology, Kobe City Medical Center General Hospital, 2Department of Ophthalmology, Institute of Biomedical Research and Innovation, 3Laborat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miyamoto N, Mandai M, Kojima H, Kameda T, Shimozono M, Nishida A, Kurimoto Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	age-related macular degeneration anti-vascular endothelial factor agent optical coherence tomography Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/083c9a7f65ff4b2e9c540b0db345595b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:083c9a7f65ff4b2e9c540b0db345595b
record_format	dspace
spelling	oai:doaj.org-article:083c9a7f65ff4b2e9c540b0db345595b2021-12-02T05:10:54ZResponse of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning1177-5483https://doaj.org/article/083c9a7f65ff4b2e9c540b0db345595b2017-04-01T00:00:00Zhttps://www.dovepress.com/response-of-eyes-with-age-related-macular-degeneration-to-anti-vegf-dr-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2 Akihiro Nishida,1,2 Yasuo Kurimoto1,2 1Department of Ophthalmology, Kobe City Medical Center General Hospital, 2Department of Ophthalmology, Institute of Biomedical Research and Innovation, 3Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan Purpose: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD).Methods: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid (“good response”) was achieved and whether recurrence was observed within 3 months (“dependent”) after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months. The measured values of the groups were compared using one-way analysis of variance with Tukey’s test to evaluate the difference between baseline and postinjection VA.Results: Among the treatment-naïve eyes, 76% had a good response to aflibercept and 37% of these were aflibercept-dependent, while 58% had a good response to ranibizumab but 51% of these were ranibizumab-dependent. Among the eyes that converted from ranibizumab treatment, 92% of the good responders to ranibizumab with dependence and 76% of the poor responders on ranibizumab had a good response to aflibercept. With aflibercept treatment, the mean VA of treatment-naïve patients was significantly better than the baseline VA over 12 months (P<0.001), and the VA of the converted group improved significantly with proactive treatment and the improvement was continuously maintained from 6 to 12 months.Conclusion: The evaluation of response to and dependence on anti-vascular endothelial growth factor therapies in AMD was useful and practical in managing therapeutic protocols to obtain a good VA. Keywords: aflibercept, ranibizumab, recurrence, dependence, visual acuity, proactive treatmentMiyamoto NMandai MKojima HKameda TShimozono MNishida AKurimoto YDove Medical Pressarticleage-related macular degenerationanti-vascular endothelial factor agentoptical coherence tomographyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 809-816 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration anti-vascular endothelial factor agent optical coherence tomography Ophthalmology RE1-994
spellingShingle	age-related macular degeneration anti-vascular endothelial factor agent optical coherence tomography Ophthalmology RE1-994 Miyamoto N Mandai M Kojima H Kameda T Shimozono M Nishida A Kurimoto Y Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
description	Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2 Akihiro Nishida,1,2 Yasuo Kurimoto1,2 1Department of Ophthalmology, Kobe City Medical Center General Hospital, 2Department of Ophthalmology, Institute of Biomedical Research and Innovation, 3Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan Purpose: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD).Methods: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid (“good response”) was achieved and whether recurrence was observed within 3 months (“dependent”) after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months. The measured values of the groups were compared using one-way analysis of variance with Tukey’s test to evaluate the difference between baseline and postinjection VA.Results: Among the treatment-naïve eyes, 76% had a good response to aflibercept and 37% of these were aflibercept-dependent, while 58% had a good response to ranibizumab but 51% of these were ranibizumab-dependent. Among the eyes that converted from ranibizumab treatment, 92% of the good responders to ranibizumab with dependence and 76% of the poor responders on ranibizumab had a good response to aflibercept. With aflibercept treatment, the mean VA of treatment-naïve patients was significantly better than the baseline VA over 12 months (P<0.001), and the VA of the converted group improved significantly with proactive treatment and the improvement was continuously maintained from 6 to 12 months.Conclusion: The evaluation of response to and dependence on anti-vascular endothelial growth factor therapies in AMD was useful and practical in managing therapeutic protocols to obtain a good VA. Keywords: aflibercept, ranibizumab, recurrence, dependence, visual acuity, proactive treatment
format	article
author	Miyamoto N Mandai M Kojima H Kameda T Shimozono M Nishida A Kurimoto Y
author_facet	Miyamoto N Mandai M Kojima H Kameda T Shimozono M Nishida A Kurimoto Y
author_sort	Miyamoto N
title	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
title_short	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
title_full	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
title_fullStr	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
title_full_unstemmed	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
title_sort	response of eyes with age-related macular degeneration to anti-vegf drugs and implications for therapy planning
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/083c9a7f65ff4b2e9c540b0db345595b
work_keys_str_mv	AT miyamoton responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT mandaim responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT kojimah responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT kamedat responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT shimozonom responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT nishidaa responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning AT kurimotoy responseofeyeswithagerelatedmaculardegenerationtoantivegfdrugsandimplicationsfortherapyplanning
_version_	1718400512217317376

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning

Ejemplares similares